ETNB
89bio, Inc. [ETNB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ETNB Stock Summary
Top 10 Correlated ETFs
ETNB
Top 10 Correlated Stocks
ETNB
In the News
ETNB Financial details
Company Rating
-
Market Cap
918.18M
Income
-197.47M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-4.92
Forward P/E
-
PEG
-12.01
P/S
-
P/B
2.18
P/C
-
P/FCF
-8.72
Quick Ratio
17.78
Current Ratio
18.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.05
EPS next Y
-
EPS next Q
-
EPS this Y
-31.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
11.11%
-
-
-
-
SMA20
26.98%
SMA50
41.34%
SMA100
55.21%
Inst Own
-
Inst Trans
-
ROA
-40%
ROE
-50%
ROC
-0.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.575-22.93
52W High
-54.82%
52W Low
+65.67%
RSI
56.37
Rel Volume
1.24
Avg Volume
1.32M
Volume
1.63M
Perf Week
-3.02%
Perf Month
15.45%
Perf Quarter
25.19%
Perf Half Y
25.82%
-
-
-
-
Beta
0.954
-
-
Volatility
0.29%, 1.03%
Prev Close
-1.09%
Price
9.94
Change
-4.42%
Company Profile
- Volume Average 1.32M
- Market Capitalization 918.18M
- Employee 70
- CEO Mr. Rohan Palekar
- Headquarters San Francisco,CA,US
- IPO Date 2019-11-11
-
Website
https://www.89bio.com 
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
